IL325099A - Oral solid estrogen receptor antagonist dosage forms - Google Patents
Oral solid estrogen receptor antagonist dosage formsInfo
- Publication number
- IL325099A IL325099A IL325099A IL32509925A IL325099A IL 325099 A IL325099 A IL 325099A IL 325099 A IL325099 A IL 325099A IL 32509925 A IL32509925 A IL 32509925A IL 325099 A IL325099 A IL 325099A
- Authority
- IL
- Israel
- Prior art keywords
- dosage forms
- oral dosage
- estrogen receptor
- solid oral
- receptor degraders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363472523P | 2023-06-12 | 2023-06-12 | |
| PCT/US2024/033417 WO2024258856A1 (fr) | 2023-06-12 | 2024-06-11 | Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325099A true IL325099A (en) | 2026-02-01 |
Family
ID=91738206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325099A IL325099A (en) | 2023-06-12 | 2025-12-03 | Oral solid estrogen receptor antagonist dosage forms |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR20260022394A (fr) |
| CN (1) | CN121311218A (fr) |
| AU (1) | AU2024303588A1 (fr) |
| IL (1) | IL325099A (fr) |
| MX (1) | MX2025014795A (fr) |
| TW (1) | TW202500155A (fr) |
| WO (1) | WO2024258856A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| MX2011009053A (es) | 2009-03-09 | 2012-04-02 | Spi Pharma Inc | Excipientes de compresion directa con alta capacidad de compactacion y durables y sistemas de excipiente. |
| AU2016272881C1 (en) * | 2015-06-04 | 2019-10-03 | Pfizer Inc. | Solid dosage forms of palbociclib |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CA3152401A1 (fr) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Procedes de traitement du cancer du sein avec des derives de tetrahydronaphtalene en tant qu'agents de degradation du recepteur des estrogenes |
| CN116390916A (zh) * | 2020-09-14 | 2023-07-04 | 阿尔维纳斯运营股份有限公司 | 用于靶向降解雌激素受体的化合物的结晶形式 |
| CN119604285A (zh) * | 2022-03-25 | 2025-03-11 | 深圳市药欣生物科技有限公司 | Protac化合物的药物组合物及其用途 |
-
2024
- 2024-06-11 AU AU2024303588A patent/AU2024303588A1/en active Pending
- 2024-06-11 TW TW113121509A patent/TW202500155A/zh unknown
- 2024-06-11 WO PCT/US2024/033417 patent/WO2024258856A1/fr active Pending
- 2024-06-11 CN CN202480038499.7A patent/CN121311218A/zh active Pending
- 2024-06-11 KR KR1020267000497A patent/KR20260022394A/ko active Pending
-
2025
- 2025-12-03 IL IL325099A patent/IL325099A/en unknown
- 2025-12-08 MX MX2025014795A patent/MX2025014795A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20260022394A (ko) | 2026-02-19 |
| WO2024258856A1 (fr) | 2024-12-19 |
| AU2024303588A1 (en) | 2025-12-18 |
| MX2025014795A (es) | 2026-01-07 |
| CN121311218A (zh) | 2026-01-09 |
| TW202500155A (zh) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL319242A (en) | Estrogen Receptor Blocker Dosage Regimen | |
| GB2595776B (en) | Therapeutic solid dosage forms | |
| ZA202102263B (en) | Oral formulations of kappa opioid receptor agonists | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| IL318878A (en) | Oral solid dosage forms containing cannabinoids | |
| IL325099A (en) | Oral solid estrogen receptor antagonist dosage forms | |
| IL320847A (en) | Oral liquid formulations of hydrocortisone | |
| CA3295229A1 (fr) | Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes | |
| ZA200705012B (en) | Oral solid dosage forms containing a low dose of estradiol | |
| IL313886A (en) | Processes for the preparation of selective compounds of estrogen receptors | |
| HK40127185A (zh) | 雌激素受体降解剂的给药方案 | |
| CA224159S (en) | Oral dosage tablet | |
| IL319657A (en) | Glucocorticoid receptor modulator formulations | |
| IL317910A (en) | Oral dosage forms of ELRAGLUSIB | |
| CA3274497A1 (fr) | Formes galéniques d'un antagoniste du récepteur des œstrogènes | |
| GB202100470D0 (en) | Solid tablet dosage for of ridinilazole | |
| IL314134A (en) | Oral dosage forms | |
| HUE066812T2 (hu) | Az utidelone szilárd, orális készítménye | |
| IL310321A (en) | Lipid-based formulation for oral administration of BRADYKININ B2 receptor antagonists | |
| AU2024325502A1 (en) | Oral pharmaceutical dosage form providing immediate release of vidofludimus | |
| CA3300667A1 (fr) | Forme posologique pharmaceutique orale fournissant une libération immédiate de vidofludimus | |
| GB202007254D0 (en) | Delivery device for units of an oral dosage form | |
| GB202004831D0 (en) | Delivery device for oral dosage forms | |
| IL325323A (en) | Solid oral podafenone formulation | |
| CA223192S (en) | Mouthpiece for oral development |